Beta Bionics (NASDAQ:BBNX) CFO Stephen Feider Sells 6,675 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. This represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The shares were sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20.

Beta Bionics Stock Performance

Shares of BBNX opened at $19.92 on Friday. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm’s 50-day simple moving average is $17.11 and its two-hundred day simple moving average is $13.61. The stock has a market cap of $896.20 million, a PE ratio of -12.07 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. Equities research analysts predict that Beta Bionics, Inc. will post -2.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. William Blair initiated coverage on shares of Beta Bionics in a research note on Friday, August 21st. They issued a “market perform” rating on the stock. Truist Financial lifted their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group upped their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Finally, UBS Group initiated coverage on shares of Beta Bionics in a research report on Tuesday, July 28th. They set a “buy” rating and a $22.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $20.10.

Institutional Trading of Beta Bionics

A number of institutional investors have recently made changes to their positions in BBNX. Summit Securities Group LLC purchased a new position in shares of Beta Bionics during the fourth quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd boosted its holdings in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after purchasing an additional 1,818 shares during the last quarter. Strs Ohio bought a new stake in Beta Bionics in the 1st quarter worth approximately $29,000. Legal & General Group Plc purchased a new stake in Beta Bionics during the 2nd quarter valued at $62,000. Finally, CIBC Private Wealth Group LLC raised its stake in Beta Bionics by 630,000.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock valued at $192,000 after buying an additional 6,300 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.